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Background: Viscous fibre in food has established health benefits, but few functional fibre preparations are both effective and
palatable. Our objective was to determine the most effective dose, formulation and timing of consumption of a novel fibre
supplement (PolyGlycopleX (PGX)) in reducing postprandial glycaemia.
Subjects/methods: Three trials were undertaken, each with 10 subjects (8M and 8F; age 24.4±2.6years). Granular supplement
was tested at four doses (0, 2.5, 5.0 and 7.5g) with breakfast (study 1). Granular and capsule forms of the supplement were
given in a single dose (5g for granules and 4.5g in capsules) at  60,  45,  30,  15 and 0 before, and þ15min after a bread
meal (study 2). Capsules at increasing doses (1.5, 3, 4.5 and 6g) were consumed with the evening meal to determine effects on
glucose tolerance at breakfast (study 3). Incremental area under the blood glucose curve was determined.
Results: Granular PGX at breakfast time at doses of 2.5, 5 and 7.5g reduced the incremental area under the curve by up to 50%
in a linear dose–response fashion (Po0.001). The granular form of PGX (5g), but not the capsules, reduced glycaemia by up to
28% when consumed from  45 to þ15min (Po0.001). Capsules containing 3, 4.5 and 6g PGX consumed with the evening
meal reduced glycaemia at breakfast by up to 28% (Po0.001).
Conclusions: PGX has biologically important, dose-related effects on acute and delayed (second meal) postprandial glycaemia.
European Journal of Clinical Nutrition (2010) 64, 1488–1493; doi:10.1038/ejcn.2010.199; published online 6 October 2010
Keywords: Viscous polysaccharide, dietary fibre, postprandial glycaemia, PGX
Introduction
Increasing evidence from long term, prospective observa-
tional studies suggests that diets containing larger quantities
of whole grains and dietary fibre are associated with reduced
risk of type 2 diabetes (Schulze et al., 2004, 2005). In
controlled trials, higher intake of cereal fibre produces
improvements in insulin sensitivity (Pereira et al., 2002),
whereas soluble fibre reduces postprandial glycaemia
(Jenkins et al., 1978), as well as serum lipids (Jenkins et al.,
1993; Vuksan et al., 1999). Most health authorities and
diabetes associations now advise an increase in dietary fibre
intake to at least 14 g per 1000 kcal (Canadian Diabetes
Association 2000; American Diabetes Association 2008).
Despite community awareness of the health benefits of
dietary fibre, intakes have remained at about half the
recommended level over the last decade (Casagrande et al.,
2007). Thus, supplementation of the diet with purified
dietary fibres that are active in vivo (that is, ‘functional’ fibre
preparations) may be an option to increase fibre intake.
Although both insoluble and soluble fibres can be used this
way, soluble fibres that develop viscosity in solution appear
to provide greater benefits for metabolism. Indeed, the
higher the viscosity, the greater the improvement in glucose
and lipid metabolism (Jenkins et al., 1978). Unfortunately, in
practice both palatability and acceptability of functional
fibres decline with increasing viscosity (Ellis et al., 1981).
Recent advances in food science suggest that optimal
viscosity can be reached by using a combination of different
viscous fibres resulting in an induced viscosity that is greater
than the viscosity of the individual components (Wood et al.,
1994). This may allow smaller doses to be used that may
increase acceptability while maintaining efficacy (Vuksan
et al., 2000).
Recently, PolyGlycopleX (PGX), a highly viscous polysac-
charide complex has been developed that demonstrates a
Received 19 April 2010; revised 7 June 2010; accepted 6 August 2010;
published online 6 October 2010
Correspondence: Professor JC Brand-Miller, Boden Institute of Obesity,
Nutrition and Exercise and the School of Molecular Bioscience, University of
Sydney, Sydney, NSW 2006, Australia.
E-mail: jennie.brandmiller@sydney.edu.au
Contributors: JCBM, SW and FSA were responsible for design of the study,
collection and analysis of the data and writing of the paper. RJG, MRL and VK
contributed to the design of the study and writing of the paper.
European Journal of Clinical Nutrition (2010) 64, 1488–1493
& 2010 Macmillan Publishers Limited All rights reserved 0954-3007/10
www.nature.com/ejcndelayed onset of peak viscosity, allowing for a more palatable
and easy-to-use functional fibre. As the effect of viscous fibre
may vary according to the conditions in the lumen of the
gastrointestinal tract, we undertook a series of studies to
investigate the effectiveness of two alternate forms of the
product (granules or capsules), the timing of the dose with
respect to that of a carbohydrate-containing meal, and the
presence or absence of a ‘second meal’ effect (that is, the
ability to reduce postprandial glycaemia the following
morning after an evening dose of the supplement).
Materials and methods
Fibre supplement
PGX (a-D-glucurono-a–manno-b-D-manno-b-D-gluco), (a-L-
gulurono-b-D mannurono), b-D-gluco-b-D-mannan; (PGX);
Inovobiologic Inc., Calgary, Canada) is a novel functional
fibre complex manufactured by a proprietary process
(EnviroSimplex) from three dietary fibres to form a highly
viscous polysaccharide with high water holding and gel-
forming properties. A proprietary process causes strong
interactions to be formed between these to produce a
resultant polysaccharide complex (Abdelhameed et al.,
2010), with a level of viscosity that is higher than any
currently known individual polysaccharide. The final
product is a novel soluble, highly viscous polysaccharide
(functional fibre) that has been shown to be well tolerated by
rodents (Matulka et al., 2009) and humans (Carabin et al.,
2009). A case study in relating pre-clinical, clinical and
postmarketing surveillance data reviewed over 54 million
serving of PGX over a 4-year period and found PGX to be
well tolerated when used to supplement the diet (unpub-
lished findings). Genotoxicity studies of PGX have shown no
mutagenic effects using bacterial reverse mutation and
mouse micronucleus assays (Marone et al., 2009). PGX is
87.4% dietary fibre, of which 81.8% is soluble. It is available
in two physical forms: a granular product that is dissolved in
water or sprinkled on food before consumption, and as a
soft-gelatin capsule that is swallowed whole.
Study design
Three single-blind, randomized controlled trials were under-
t a k e ni nt h r e eg r o u p so f1 0h e a l t h ys u b j e c t ss e l e c t e df r o map o o l
of 16 (8M and 8F; age 24.4±2.6 years (range: 20.3–29.2 years);
body mass index 21.7±2.3kg/m
2 (range: 18.2–24.8kg/m
2)).
Subjects were recruited through the Sydney University
Glycemic Index Research Service volunteer roster. Entry
criteria included body mass index o 25kg/m
2 and fasting
blood glucose o5.5mmol/l. Subjects taking medications
or dietary supplements were excluded. The study was
conducted at the University of Sydney and was approved
by the Human Research Ethics Committee of the University
of Sydney. Informed written consent was obtained from all
subjects before the start of the study. Subjects received
a small financial reward for their participation.
Treatments were randomized within each series with 6, 7
a n d1 6t r e a t m e n t si ns t u d y1 ,2a n d3 ,r e s p e c t i v e l y .E a c h
subject undertook up to two tests per week with at least 2 days
b e t w e e nt e s t s .O ne a c ht e s td a y ,s u b j e c t sa r r i v e da tt h e
metabolic kitchen in the morning after a 10–12h overnight
fast. After being weighed and having two fasting blood samples
obtained by finger-prick, the subject consumed the test meal
within 10min, and further blood samples were obtained at 15,
30, 45, 60, 90 and 120min after the start of eating.
Study 1. The aim was to investigate the dose–response
relationship using four doses of PGX granules taken with a
white bread meal (Tip Top, George Weston Foods, Sydney,
NSW, Australia) containing 50g available carbohydrate
(defined as total carbohydrate minus dietary fibre). There
were six treatments consisting of three placebo tests (0g) and
one each with 2.5, 5 and 7.5g supplement. The active
granules were dissolved in 2 250ml glasses of water.
Study 2. The aim was to determine whether the timing of a
single dose of PGX (5g) was critical, and whether the ability
to lower postprandial glycaemia (effectiveness) varied with
the form of the supplement (capsules or granules). Of the 16
treatments, four were placebo, six were capsules and six were
granules, given at times  60,  45,  30,  15, 0 and þ15min
relative to the start of eating. The meal consisted of a 50g
available carbohydrate portion of white bread. The granular
supplement was dissolved in 2 250ml water and consumed
within 5min, whereas capsules were consumed with the
same volume of water (0 time).
Study 3. The aim was to investigate whether increasing
amounts of the capsule form of PGX had a ‘second meal’
effect, that is, a beneficial effect on glucose tolerance at
breakfast following supplementation at the previous evening
meal. Subjects underwent a total of seven sessions in which
the same meal (teriyaki chicken stir-fry with vegetables and
Jasmine rice, with a cereal snack bar for dessert) containing
120g available carbohydrate and 3000kJ (approximately 717
Cal) (female meal) and 3300kJ (approximately 789 Cal)
(male meal) was consumed in the evening together with 1.5,
3, 4.5 or 6g of PGX (2, 4, 6 and 8 capsules, respectively, given
in random order) or 4, 6 or 8 placebo capsules (that is, a total
of three placebo tests) and 2 250ml water. The evening
meal was consumed within 20min and the capsules were
taken at the start of the meal. On the following morning
after a 12-h fast, subjects consumed a standard breakfast of
white bread containing 50g available carbohydrate.
Blood glucose analysis
Finger-prick blood samples (0.8ml) from warmed hands were
collected into Eppendorf tubes containing 10U heparin,
centrifuged and the plasma stored on ice until same-day
analysis in duplicate using a glucose hexokinase assay (Roche
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matic centrifugal spectrophotometric analyser (Roche/
Hitachi 912, Boehringer Mannheim Gmbh, Germany) with
internal controls.
Statistical analysis
For each test, the incremental area under the curve (iAUC)
was calculated according to the trapezoidal method. Any
area under the baseline (fasting value) was ignored. In each
study, the results were analyzed using a general linear
model (analysis of variance) for iAUC with treatment or
food and time as fixed factors and subject as a random
factor. PASW Statistics 18 (SPSS Inc., Chicago, IL, USA) was
used for all statistical analyses. Results are expressed as
means±s.e.m.
Results
Study 1 investigated the dose–response effect of 0, 2. 5, 5 and
7.5g of the granular form of PGX dissolved in water and
taken with the meal. The highest dose reduced the iAUC by
50% from 151±5t o7 6 ±9m M/120min (Po0.005). Treating
dose as a continuous variable with values 0, 1, 2 and 3, there
was a significant linear reduction of postprandial glycaemia
(iAUC 151±5, 113±9, 88±9 and 76±9m M/120min,
Po0.001, Figure 1) with each additional gram of supplement
reducing iAUC by B11 units or 7%. In pairwise comparisons,
adjacent doses were not significantly different, but all other
comparisons were significant at P¼0.005.
Study 2 determined whether the timing of a single dose
(5g) relative to the meal influenced postprandial glycaemia,
and whether the physical form of the supplement (capsules
or granules) was important. The granular form, but not the
capsules, significantly reduced glycaemia relative to placebo
(Po0.001) when consumed at  45,  30,  15, 0 or þ15min,
but not –60min, relative to the meal (Figure 2a). The most
effective reduction in iAUC occurred when the granules were
consumed at the start of the meal (0 time, 28% reduction,
145±5 vs 103±11mM/120min, Po0.001), followed by  30
and 15min. There was no significant effect of capsules,
irrespective of timing (Figure 2b).
Study 3 determined whether there was a ‘second meal’
effect at breakfast following supplementation with capsule
form in the previous evening meal. Doses of 3, 4.5 and 6g
(but not 1.5g) reduced blood glucose iAUC relative to
placebo (171±4 (0g), 150±8 (3g), 130±8 (4.5g) and
123±8( 6 g ) m M/120min, respectively), with the greatest
reduction seen with the largest number of capsules (Figure 3).
There was a significant dose–response effect at the second
meal, indicating that each extra active capsule reduced the
incremental AUC by B6 units or B3–4%.
Adverse events
Although no formal assessment was made, all test meals were
well tolerated and no adverse events were reported.
Discussion
This series of studies shows that PGX has clinically
important, dose-related effects on acute and delayed post-
prandial glycaemia. The highest dose of the granular form
(7.5g) dissolved in water and consumed with a carbohydrate
meal at breakfast time, reduced the blood glucose response
in healthy individuals by 50%. Effectiveness of PGX granules
was also related to timing: consumption within 15min of
the start of the meal, but not 45 or 60min, reduced
glycaemia just as effectively as when taken with the meal
(0 time). In contrast, PGX (4.5g) consumed as capsules did
not produce acute lowering of glycaemia, yet had important
‘second meal’ effects, improving glucose tolerance at
breakfast time when consumed with the previous evening
meal. These findings indicate that the effectiveness of
PGX is dependent on dose, timing of consumption and
physical form.
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Figure 1 Acute dose–response effects. Incremental postprandial blood glucose responses and corresponding incremental area under the curve
(iAUC) of 10 healthy subjects after four meals containing 50g available carbohydrate as white bread supplemented with 0, 2.5, 5 or 7.5g of PGX
granules dissolved in 500ml of water. Columns with different letters are significantly different (Po0.01). P-values are for analysis of variance with
pairwise comparisons.
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European Journal of Clinical NutritionThe magnitude of the reduction in glycaemia achieved
with PGX appears to be comparable with or superior to
other commercially available functional fibre preparations
(Jenkins et al., 1978). High viscosity guar gum (B5g) also
reduces glycaemia by up to 50% when intimately mixed with
a meal, but it is not effective when viscosity is low (Leclere
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Figure 2 Timing of consumption. Incremental postprandial blood glucose responses and corresponding incremental area under the curve
(iAUC) of 10 healthy subjects after a meal containing 50g available carbohydrate as white bread supplemented at  60,  45,  30,  15, 0 and
þ15min with PGX granules (5g) dissolved in 500ml of water (a) and as PGX capsules consumed with 500ml water (b). Bars with different
letters are significantly different (Po0.001). P-values are for analysis of variance with pairwise comparisons.
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Figure 3 Delayed ‘second meal’ effects. Incremental postprandial blood glucose responses and corresponding incremental area under the
curve (iAUC) of 10 healthy subjects after a standard breakfast containing 50g available carbohydrate as white bread. On the evening before the
breakfast, 0, 1.5, 3, 4.5 and 6g PGX in the form of capsules were consumed with the evening meal. Bars with different letters are significantly
different (Po0.01). P-values are for analysis of variance with pairwise comparisons.
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European Journal of Clinical Nutritionet al., 1994). In contrast, pysllium fibre (5g) produced only a
14% reduction in postprandial glycaemia when consumed
with a breakfast meal (Pastors et al., 1991). b-glucans (5g)
derived from oats, but not barley, reduced glycaemia
by o20% when consumed with a bread meal (Biorklund
et al., 2005).
The beneficial effects of functional fibre preparations are
highly dependent on the food matrix. PGX has also been
found to be just as effective when sprinkled on food as
dissolved in water (unpublished data). This ability provides
a significant advantage in terms of palatability because it
delays the onset of viscosity. Nonetheless, PGX was not
effective when consumed encased in gelatin capsules, even
when a 15, 30, 45 or 60-min time gap was permitted between
consumption of the capsules and the start of the meal to
allow development of viscosity in vivo.
The effectiveness of various fibre preparations has been
directly related to their ability to create viscosity (Jenkins
et al., 1978). Nonetheless, extreme viscosity is not desirable.
Guar gum is so highly viscous that its applications are
limited because of the difficulties in incorporating the
product into normal food processing operations. To be
effective, guar gum must be mixed with a blender to prevent
clumps, and allowed to reach its full viscosity before
incorporation, often resulting in an undesirable food texture
or mouth-feel. In contrast, the present studies show that
PGX reduces glycaemia very effectively when consumed in
water before significant gelling has taken place. Guar is also
noted for its capacity to produce excessive gastrointestinal
discomfort (Ellis et al., 1981). In a double blind, randomized
controlled trial (n¼54), gastrointestinal symptoms after
PGX supplementation were rated as mild to moderate, and
generally well tolerated (Carabin et al., 2009).
In the third study in this series, we showed that PGX in
capsule form had dose-related ‘second meal’ effects. This
phenomenon describes the ability of a food or supplement to
improve glucose tolerance at the following meal, for
example, from dinner in the evening to breakfast the next
day or from breakfast to lunch or lunch to dinner on the
same day. In the case of PGX, 6g consumed as capsules in the
evening reduced glycaemia at breakfast by almost 30%. This
is a useful attribute because it implies that not all meals must
be consumed with the supplement in order to see benefits on
postprandial glycaemia. Many fibres, both soluble and
insoluble, as well as low glycaemic index foods, have been
shown to produce second meal effects (Brighenti et al.,
2006). The effect of wheat fibre is thought to be directly
related to an acute improvement (within 24h) in whole-
body insulin sensitivity caused by the absorption of the
products of fermentation of the fibre in the large bowel into
the portal bloodstream (Weickert et al., 2005). In the case of
low glycaemic index foods, the mechanism may be related to
prolonged carbohydrate absorption and suppression of free
fatty acid release (Jenkins et al., 1990). It is, therefore,
possible that the second meal effects of PGX could be even
greater in the granular form.
In the past, the ability of fibre preparations to improve
lipid metabolism was the focus of most research (Brown
et al., 1999). But increasingly, reductions in postprandial
glycaemia (glycemic ‘spikes’) have been encouraged as part
of the management and prevention of impaired glucose
tolerance (pre-diabetes) and type 2 diabetes (Ceriello, 2004;
Dickinson and Brand-Miller, 2005). In the STOP-NIDDM
trial, treatment with the a-glucosidase inhibitor, acarbose, a
compound that specifically reduces postprandial hypergly-
caemia, reduced the risk of type 2 diabetes (Chiasson et al.,
2002), weight gain over time (Chiasson et al., 2002, 2003),
and cardiovascular disease (Chiasson et al., 2003). The
repeated challenge to b-cell function induced by low-fibre,
high-carbohydrate meals is of concern in insulin-resistant
individuals who must increase insulin secretion to
re-establish glucose homeostasis. In this phenotype, adher-
ence to a conventional low fat diet produces both higher
postprandial glycaemic and insulinaemic excursions and
greater demands on b-cell function, which could eventually
promote b-cell dysfunction and type 2 diabetes. PGX’s ability
to reduce postprandial glycaemia also suggests a potential
role in the treatment and prevention of obesity. Low
glycaemic index carbohydrates have been associated with
lower fat mass accretion in animal models (Pawlak et al.,
2004; Isken et al., 2009) and greater fat loss in some weight
loss trials (McMillan-Price et al., 2006; Ebbeling et al., 2007).
In adolescents, PGX in solution (5g) was shown to reduce
energy intake from a pizza meal given 90minutes later more
effectively than less viscous fibres, such as glucomannan and
cellulose (Vuksan et al., 2009).
In conclusion, PGX in granular form has biologically
important, dose-related effects on acute postprandial glycae-
mia. As little as 7.5g of the granules reduces blood glucose
responses over 120min by 50%. Precise timing was not
critical and consumption within 15min either side of the
start of the meal was effective. PGX in capsule form did
not reduce acute glycaemia with the meal it was taken with
but had a biologically important effect when consumed with
the evening meal whereby it improved glucose tolerance at
breakfast (that is, a ‘second meal effect’). Further research is
needed to evaluate the long-term health benefits of this
promising viscous polysaccharide.
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